NVS

Novartis AG Q1 2007 Financial Summary

Business Context and Reporting Period

This Form 6-K filing reports the unaudited financial results for Novartis AG for the first quarter ended March 31, 2007. The company is a global leader in healthcare, focusing on innovative pharmaceuticals, generics, vaccines, and consumer health products. During this period, Novartis completed its strategic repositioning to focus exclusively on healthcare, finalizing the divestment of non-core businesses including the agreement to sell the Gerber baby foods business to Nestlé in April 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Group net sales rose 18% (15% in local currencies), driven by volume (+10%), acquisitions (+5%), and currency translation (+3%). All divisions contributed, with Pharmaceuticals (+17%) and Sandoz (+19%) leading growth.
• Profitability: Operating income grew 11%, lagging sales growth primarily due to a one-time divestment gain of $129 million in Q1 2006 that was not repeated. Continuing operations operating income grew 18%.
• Divisional Performance:
  • Pharmaceuticals: Sales of $5.9 billion; top products Diovan (+20% lc) and Gleevec (+16% lc) drove growth. A $52 million charge was taken for Zelnorm suspension, offset by a $107 million gain from Tekturna inventory provision reversal.
  • Sandoz: Sales of $1.7 billion; operating income surged 34% due to new product launches and productivity gains.
  • Vaccines & Diagnostics: Sales of $231 million; operating income included a $67 million legal settlement gain.
• Cash Flow: Operating cash flow from continuing operations increased to $2.2 billion. However, total free cash flow turned negative (-$256 million) compared to a positive $373 million in Q1 2006, largely due to dividend payments ($1.8 billion) and share repurchases ($0.8 billion).

Guidance, Outlook, and Risks

• Outlook: Management reaffirms expectations for record 2007 operating and net income from continuing operations. The outlook for Group net sales growth remains above 5% in local currencies, despite the Zelnorm suspension.
• Zelnorm Impact: The FDA requested a suspension of Zelnorm sales in the US and seven other countries. Management estimates this will reduce 2007 net sales by more than $600 million. A $52 million charge was recognized in Q1 2007.
• Regulatory Approvals: Four key approvals received in Q1: Tekturna (US), Lucentis (EU), Exforge (EU), and Sebivo (China). Galvus (diabetes) received an "approvable letter" but requires additional data.
• Divestments: The Gerber divestment (agreed April 12, 2007) is expected to complete in H2 2007. The Medical Nutrition divestment is also pending completion in 2007.
• Risks: Forward-looking statements are subject to risks including clinical trial results, regulatory delays, patent challenges (e.g., Lotrel), and pricing pressures.

Investor Verification Checklist

• Zelnorm Suspension: Verify the ongoing impact of the Zelnorm suspension on Q2 and full-year revenue projections and potential legal liabilities.
• Gerber Divestment: Confirm the closing date and final sale price of the Gerber business unit to Nestlé, and ensure proper classification as a discontinuing operation in future filings.
• One-Time Items: Review the sustainability of operating income growth by excluding the $107 million Tekturna inventory gain and the $67 million legal settlement in Vaccines.
• Free Cash Flow: Monitor the trend in free cash flow given the significant outflow in Q1 2007 driven by capital returns (dividends/buybacks) versus organic generation.
• Patent Expirations: Assess the impact of upcoming generic competition for key products like Lotrel (patent expired March 2007) and Trileptal (expected mid-2007).